RecruitingPhase 1NCT06319872

The Effects of Disulfiram (Antabuse®) on Visual Acuity in Patients With Retinal Degeneration

The Effects of Disulfiram on Visual Acuity in Patients With Retinal Degeneration

Sponsor

University of Rochester

Enrollment

15 participants

Start Date

May 19, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

Oral disulfiram (Antabuse®) has been shown to improve image-forming vision in animal models with retinal degeneration due to its ability to decrease Retinoic Acid synthesis and consequently reduce hyperactivity in the inner retina. The investigator will aim to evaluate the impact of oral disulfiram on the vision of patients with retinal degeneration who are being treated with the drug in the management of their concurrent alcohol use disorder.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Oral disulfiram for people with age-related macular degeneration, alcohol use disorder, and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGOral disulfiram

250 mg/day

Locations(1)

Flaum Eye Institute, University of Rochester Medical Center

Rochester, New York, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06319872

Related Trials

Temporally-Resolved Electrophysiology of Acamprosate Treatment of Alcohol Use Disorder

NCT062696271 location

Semaglutide Therapy for Alcohol Reduction (STAR)

NCT060158931 location